Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again

Executive Summary

Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.

You may also be interested in...



With Telemedicine, Hospitals May Have More Flexible Access To 340B Drug Discounts

But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?

Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?

PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.

340B Reform May Return To Capitol Hill: Hearings Will Play To New HRSA Leadership

Rep. Chris Collins (R-NY) plans to introduced a bill to reform the 340B drug discount program in the coming weeks, and says he has a commitment from the House Energy & Commerce Committee leadership to consider the bill in hearings over the summer; that in turn may help shape HRSA’s oversight of the program in the Trump Administration.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel